OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
J Venom Res
Open-access
Aptamers
Open-access
The Eur J Extracellular Vesicles
Open-access
Submit a manuscript

By

admin
METHOD ISSN: 2514-3247 Aptamers (2019), Vol 3, 10-16 Published online: 20 December 2019 Full Text Access Zhesen Tan, Trevor A Feagin, Jennifer M Heemstra* Department of Chemistry, Emory University, Atlanta, Georgia, USA *Correspondence to: Jennifer Heemstra, Email: jen.heemstra@emory.edu, Tel: + 404 727 7766 Received: 15 June 2019 | Revised: 05 December 2019 | Accepted: 06 December 2019 ©...
Read More
TECHNICAL REPORT ISSN: 2514-3247 Aptamers (2019), Vol 3, 04-09 Published online: 23 November 2019 Full Text Access Justin Henri 1, Narges Bayat 3, 4, Joanna Macdonald 1, 2, and Sarah Shigdar 1,2,* 1 School of Medicine Deakin University, Geelong, Victoria 3128, Australia 2 Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria, 3216, Australia 3...
Read More
We are delighted and honoured that Professor Larry Gold will deliver a keynote address at Aptamers 2020. He will also receive a Lifetime Achievement Award on behalf of the International Society on Aptamers (INSOAP) for is pioneering and extraordinary contributions to the field of aptamers and therapeutics. Dr Larry Gold is the Founder and Chairman...
Read More
We are delighted to announce that Dr Nebojsa Janjic will chair Aptamers 2020. Dr Nebojsa Janjic is the Chief Science Officer at SomaLogic. Prior to joining SomaLogic, Dr Janjic was the CSO at Replidyne, Inc, a biotechnology company focusing on the development of small-molecule antibacterial agents. Prior to Replidyne, he was Senior Director of Drug Discovery...
Read More
MEETING REVIEW ISSN: 2514-3247 Aptamers (2019), Vol 3, 01-03 Published online: 14 July 2019 Full Text Access Sarah Shigdar 1,2, Philip Johnson 3, Georg Pietruschka 4, Tjaša Legen 4, Günter Mayer 4, Maureen McKeague 5,6 1 School of Medicine Deakin University, Geelong, Victoria 3128, Australia 2 Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria...
Read More
The INSOAP’s Aptamers meeting has been running at Oxford since 2014, and has attracted attendance from several key scientists in the field, industry researchers, solution providers, and young and emerging researchers. We are now inviting proposals for chairing the 2020 meeting. If you are interested in chairing it, or would like to suggest a chair,...
Read More
Fee Structure Early bird and group discounts are available. Register 3 for the price of 2 until 31 December 2019 (cheapest registration free – Promocode: 3for2)* Register 4 for the price of 3 any time (cheapest registration free – Promocode: 4for3)* Fees apply to payments made on or before the indicated deadlines and not to...
Read More
TAGCyx Biotechnologies Inc. is a drug discovery and development company based in Japan, spun out of Riken Research Institute. We utilizes its proprietary, artificial nucleotide base pair technology invented by Dr. Ichiro Hirao to generate unique DNA aptamer, Xenoligo®, for therapeutic purposes.  Amongst various type of aptamers, the advantage of Xenoligo® are: 1) comprised of DNA,...
Read More
ATDBio was established to provide high quality oligonucleotides to scientists around the world. ATDBio oligonucleotides are used successfully in academic and commercial research in the fields of genetics, genomics, molecular biology, biochemistry, biotechnology and nanotechnology. We supply a wide range of custom-made unmodified and chemically modified oligonucleotides for small and large scale applications. ATDBio specialises in highly...
Read More
RIBOMIC Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies called the RiboART System. RIBOMIC has been promoting the pharmaceutical discovery program in collaboration with Otsuka Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., The University of Tokyo, and some...
Read More
1 2 3 4 5 11

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases